Assessing cellular protein phosphorylation: High throughput drug discovery technologies

Assay and Drug Development Technologies

Volumn 2, Issue 2, 2004, Pages 225-235

  Russello, Salvatore V ^a  

^a CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HYDROGEN PEROXIDE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANALYTIC METHOD; ARTICLE; CANCER; CELL FUNCTION; CELL LYSATE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MECHANISM; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MEDICAL TECHNOLOGY; METABOLIC DISORDER; MOLECULAR SIZE; NONHUMAN; PATHOLOGY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 2442612550     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/154065804323056567     Document Type: Article

References (60)

1. Hunter T: Signaling - 2000 and beyond. Cell 2000;100: 113-127.
2. Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
3. Blume-Jensen P, Hunter T: Oncogenic kinase signaling. Nature 2001;411:355-365.
4. Dancey J, Sausville E: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.
5. Burke J: Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Devel 2003;6:720-728.
6. Karin M, Yamamoto Y, Wang Q: The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
7. Hu E, Lee D: Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. Curr Opin Investig Drugs 2003;4:1065-1075.
8. High Throughput Screening 2000: New Trends and Directions. High Tech Business Decisions, Morgan, CA, 2000.
9. Walters W, Namchuk M: Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2003;2:259-266.
10. Wylie P: High-content screening: advantages of whole cell analysis. Curr Drug Discov 2004;January:9-10.
11. Sreekumar A, Chinnaiyan A: Protein microarrays: a powerful new tool to study cancer. Curr Opin Mol Ther 2002;4: 587-593.
12. Ng J, Ilag L: Biochips beyond DNA: technologies and applications. Biotechnol Annu Rev 2003;9:1-149.
13. Cutler P: Protein arrays: the current state-of-the-art. Proteomics 2003;3:3-18.
14. Nishizuka S, Charboneau L, Young L, Major S, Reinhold W, Waltham M, Kouros-Mehr H, Bussey K, Lee J, Espina V, Munson P, Petricoin E, Liotta L, Weinstein J: Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003;100:14229-14243.
15. Espina V, Mehta A, Winters M, Calvert V, Wulfkuhle J, Petricoin E, Liotta L: Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3:2091-2100.
16. Zhou H, Watts J, Aebersold R: A systematic approach to the analysis of protein phosphorylation. Nat Biotechnol 2001;19:375-378.
17. Kalume D, Molina H, Pandy A: Tackling the phosphoproteome: tools and strategies. Curr Opin Chem Biol 2003;7: 64-69.
18. Ross A, Baltimore D, Eisen H: Phosphotyrosine-containing proteins isolated by affinity chromatography with antibodies to a synthetic hapten. Nature 1981;294:654-656.
19. Sternberger L, Sternberger N: Monoclonal antibodies distinguish phosphorylated and non-phosphorylated forms of neurofilaments in situ. Proc Natl Acad Sci U S A 1983; 80:6126-6130.
20. White M, Backer J: Preparation and use of anti-phosphotyrosine antibodies to study structure and function of insulin receptor. Methods Enzymol 1991;201:65-79.
21. Frackelton A, Poster M, Kannan B, Mermelstein F: Generation of monoclonal antibodies against phosphotyrosine and their use for affinity purification of phosphotyrosine containing proteins. Methods Enzymol 1991;201:79-92.
22. Glenney J: Isolation of tyrosine-phosphorylated proteins and generation of monoclonal antibodies. Methods Enzymol 1991;201:92-100.
23. Kanner S, Reynolds A, Parsons J: Immunoaffinity purification of tyrosine-phosphorylated cellular proteins. J Immunol Methods 1989;120:115-124.
24. Kamps MP: Generation and use of anti-phosphotyrosine antibodies for imunoblotting. Methods Enzymol 1991;201: 101-110.
25. Czernik A, Girault J, Nairn A, Chen J, Snyder G, Kebabian J, Greengard P: Production of phosphorylation state-specific antibodies. Methods Enzymol 1991;201:264-283.
26. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2: 566-580.
27. Mandell J: Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003;163:1687-1698.
28. King I, Feng M, Catino J: High throughput assay for inhibitors of the epidermal growth factor receptor-associated tyrosine kinase. Life Sci 1993;53:1465-1472.
29. Angeles T, Lippy J, Yang S: Quantitative, high-throughput cell-based assays for inhibitors of trkA receptor. Anal Biochem 2000;278:93-98.
30. Sadler T, Achilleos M, Ragunathan S, Pitkin A, LaRocque J, Morin J, Annable R, Greenberger L, Frost P, Zhang Y: Development and comparison of two nonradioactive kinase assays for I kappa B kinase. Anal Biochem 2004;326:106-113.
31. Braunwalder A, Yarwood D, Sills M, Lipson K: Measurement of protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates. Anal Biochem 1996;238:159-164.
32. Yamamoto N, Hasegawa H, Seki H, Zieglbauer K, Yasuda T: Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors. Anal Biochem 2003;315:256-261.
33. Waddelton D, Ramachandran C, Wang Q: Development of a time-resolved fluorescent assay for measuring tyrosine-phosphorylated proteins in cells. Anal Biochem 2002;309: 150-157.
34. Minor L, Westover L, Kong Y, Patel D, Wildey M, Conway B, Demarest K: Validation of a cell-based screen for insulin receptor modulators by quantification of insulin receptor phosphorylation. J Biomol Screen 2003;8:439-446.
35. Minor L: Assays to measure the activation of membrane tyrosine kinase receptors: focus on cellular methods. Curr Opin Drug Discov Devel 2003;6:760-765.
36. Levine A: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
37. Bulavin D, Higashimoto Y, Popoff I, Gaarde W, Basrur V, Potapova O, Apella E, Fornace A: Initiation of G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001;411:102-107.
38. Tibbetts R, Brumbaugh K, Williams J, Sarkaria J, Cliby W, Shieh S, Taya Y, Prives C, Abraham R: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152-157.
39. Burgering B, Coffer P: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:553-554.
40. Armstrong B, Stewart M, Mazumder A: Suspension arrays for high throughput, multiplexed single nucleotide polymorphism genotyping. Cytometry 2000;40:102-108.
41. Carson R, Vignali D: Simultaneous quantification of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods 1999;227:41-52.
42. Bio-Plex Technology and Collaborations with Cell Signaling Technology. News of the Alliance for Cellular Signaling 2003;3:3-4.
43. Ricco A, Boone T, Fan Z, Gibbons I, Matray T, Singh S, Tan H, Tian T, Williams S: Application of disposable plastic microfluidic device arrays with customized chemistries to multiplexed biochemical assays. Biochem Soc Trans 2001;30:73-78.
44. Nolan J, Sklar L: Suspension array technology: evolution of the flat-array paradigm. Trends Biotechnol 2002;20:9-12.
45. Stockwell B, Haggarty S, Schreiber S: High-throughput screening of small molecules in miniaturized mammalian cell-based assay involving post-translational modifications. Chem Biol 1999;6:71-83.
46. Versteeg HH, Nijhuis E, van der Brink GR, Evertzen M, Pynaert GN, van Deventer SJ, Coffer PJ, Peppelenbosch MP: A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 2000;350:717-722.
47. Barrie S, Eno-Amooquaye E, Hardcastle A, Platt G, Richards J, Bedford D, Workman P, Aherne W, Mittnacht S, Garret M: High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. Anal Biochem 2003;320:66-74.
48. Huezo H, Vilenchik M, Rosen N, Chiosis G: Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chem Biol 2003;10:629-634.
49. Liu R, Hsieh C, Lam K: New approaches in identifying drugs to inactivate oncogene products. Semin Cancer Biol 2004;14:13-21.
50. Vogt A, Adachi T, Ducruet A, Chesebrough J, Nemoto K, Carr B, Lazo J: Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. J Biol Chem 2001;276:20544-20550.
51. Vogt A, Cooley K, Brisson M, Tarpley M, Wipf P, Lazo J: Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol 2003;10:733-742.
52. Giuliano K: high-content profiling of drug-drug interactions: cellular targets involved in the modulation of microtubule drug action by the antifungal ketoconazole. J Biomol Screen 2003;8:125-134.
53. Zarkowska T, Harlow U, Mittnacht S: Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Oncogene 1997;14:249-254.
54. Fry D, Bridges A, Denny W, Doherty A, Greis K, Hicks J, Hook K, Keller P, Leopold W, Loo J, McNamara D, Nelson J, Sherwood V, Smaill J, Trumpp-Kallmeyer S, Dobrusin E: Specific irreversible inactivation of the epidermal growth factor receptor and erbB2 by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A 1998; 95:12022-12027.
55. Arteaga C, Khuri F, Krystal G, Sebti S: Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol 2002;29:15-26.
56. Teruel M, Meyer T: Translocation and reversible localization of signaling proteins: a dynamic future for signal transduction. Cell 2000;103:181-184.
57. Karin M, Hunter T: Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 1995;5:747-757.
58. Levitski A: Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002;38(Suppl 5):S11-S18.
59. Al-Obeidi F, Lam K: Development of inhibitors for protein tyrosine kinases. Oncogene 2000;19:5690-5701.
60. Zhang H, Zha X, Tan Y, Hornbeck P, Mastrangelo A, Alessi D, Polakiewicz R, Comb M: Phosphorylation analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem 2002;42:39379-39387.